Lamotrigine for cognitive deficits associated with neurofibromatosis type 1: A phase <scp>II</scp> randomized placebo‐controlled trial
Lamotrigine did not improve cognitive functioning in adolescents with NF1. The small treatment effects make it unlikely that a larger sample size could have changed this conclusion.
Authors
- Thijs van der Vaart (ORCID: https://orcid.org/0000-0002-3858-4027)
- Federico Ramos (ORCID: https://orcid.org/0000-0001-5950-8827)
- Rianne Oostenbrink (ORCID: https://orcid.org/0000-0001-7919-8934)
- André B. Rietman (ORCID: https://orcid.org/0000-0002-9004-0836)
- A Parra (ORCID: https://orcid.org/0009-0000-7895-9746)
- Henriëtte A. Moll (ORCID: https://orcid.org/0000-0001-9304-3322)
- Eric Legius (ORCID: https://orcid.org/0000-0003-2410-6996)
- Ype Elgersma (ORCID: https://orcid.org/0000-0002-3758-1297)
- Sabine E. Mous (ORCID: https://orcid.org/0000-0002-9088-8095)
- Jesminne Castricum (ORCID: https://orcid.org/0000-0001-6923-9878)
- Myrthe J. Ottenhoff (ORCID: https://orcid.org/0000-0003-1934-7752)
- Marie‐Claire Y. de Wit (ORCID: https://orcid.org/0000-0002-9042-4813)
- Joke H. M. Tulen (ORCID: https://orcid.org/0009-0001-8488-6536)
Institutions
- Hospital Sant Joan de Déu Barcelona (ES)
- Erasmus MC (NL)
- Erasmus MC - Sophia Children’s Hospital (NL)
- Erasmus University Rotterdam (NL)
- KU Leuven (BE)
Publication Details
- Journal
- Developmental Medicine & Child Neurology
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1111/dmcn.16094
- Citations
- 5
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 1.85
Funders
- ZonMw